Brief: Celularity Announces FDA Clearance Of Investigational New Drug Application For Natural Killer Cell Therapy CYNK-101
29/11/2021 13:03
Nov 29 (Reuters) - Celularity Inc CELU.O :
* CELULARITY ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW
DRUG
APPLICATION (IND) FOR NATURAL KILLER CELL THERAPY CYNK-101 IN
FIRST-LINE ADVANCED HER2/NEU POSITIVE GASTRIC AND
GASTROESOPHAGEAL JUNCTION CANCER
* CELULARITY ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW
DRUG
APPLICATION (IND) FOR NATURAL KILLER CELL THERAPY CYNK-101 IN
FIRST-LINE ADVANCED HER2/NEU POSITIVE GASTRIC AND
GASTROESOPHAGEAL JUNCTION CANCER
Source text for Eikon: ID:nGNX2PsMw6
Further company coverage: CELU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celularity
See all newsU.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Celularity hits over 4-month high on deal to manufacture MuseCell's cell therapy platform
Celularity rises on deal to manufacture MuseCell's cell therapy platform
Brief: Celularity And MuseCell Innovations® Announce U.S. Manufacturing Collaboration For The Dezawa Musecell® Platform